# Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

> **NCT00073983** · PHASE2 · COMPLETED · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 54 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** docetaxel
- **DRUG:** gemcitabine hydrochloride
- **GENETIC:** microarray analysis
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacokinetic study

## Key facts

- **NCT ID:** NCT00073983
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2012-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073983, "Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00073983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*